Nasobec Hayfever (Beclometasone Dipropionate)

Beclometasone dipropionate binds to glucocorticoid receptors in nasal mucosal cells, altering gene expression to suppress inflammatory cytokines, reduce vascular leakage, and inhibit immune cell activation. This anti‑inflammatory effect diminishes swelling and mucus production, easing allergy symptoms.

The prescribed dose of Nasobec Hayfever is determined by a qualified healthcare professional based on the severity of symptoms and individual patient factors. Patients should follow the prescriber's instructions and not adjust the dose on their own.

Safety data for beclometasone dipropionate in pregnancy and lactation are limited. Healthcare providers will weigh potential benefits against risks before prescribing. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their doctor.

To order Nasobec Hayfever, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasobec Hayfever contains beclometasone dipropionate, which offers potent anti‑inflammatory activity comparable to other intranasal corticosteroids such as fluticasone or mometasone. Choice of product often depends on physician preference, patient tolerance, dosing frequency, and specific formulation characteristics.

Store Nasobec Hayfever at ambient temperature, below 25 °C. Keep the spray in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed to maintain product stability.

Nasobec Hayfever is administered as a nasal spray. The patient gently inserts the nozzle into one nostril, inhales gently, and actuates the spray while breathing in. The recommended number of sprays per nostril is provided by the prescriber.

Serious but rare risks include nasal septal perforation, severe allergic reactions such as anaphylaxis, cataracts or glaucoma with long‑term use, and systemic adrenal suppression. Patients should report any unusual symptoms, especially visual changes or persistent nosebleeds, to their healthcare provider.

Nasobec Hayfever should be avoided in individuals with known hypersensitivity to beclometasone dipropionate or any component of the formulation, and in patients with active untreated nasal infections. Consultation with a healthcare professional is essential before starting therapy.